Literature DB >> 17580270

Mucoid Pseudomonas in cystic fibrosis.

Bobbi Pritt1, Linda O'Brien, Washington Winn.   

Abstract

Pseudomonas aeruginosa is a frequent and virulent pulmonary pathogen in patients with cystic fibrosis. If colonization is not prevented, P aeruginosa becomes permanently established and nearly always mutates into a mucoid strain. The alginate-containing matrix of the mucoid strain is thought to allow the formation of protected microcolonies and provide increased resistance to opsonization, phagocytosis, and destruction by antibiotics. As a result, conversion to the mucoid phenotype is associated with a significant increase in morbidity and mortality. In the microbiology laboratory, mucoid P aeruginosa has a distinct Gram stain and culture appearance that can expedite its identification and facilitate appropriate patient management. Important aspects of the mucoid phenotype are reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580270     DOI: 10.1309/KJRPC7DD5TR9NTDM

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  33 in total

1.  Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity.

Authors:  Brendan D Snarr; Perrin Baker; Natalie C Bamford; Yukiko Sato; Hong Liu; Mélanie Lehoux; Fabrice N Gravelat; Hanna Ostapska; Shane R Baistrocchi; Robert P Cerone; Elan E Filler; Matthew R Parsek; Scott G Filler; P Lynne Howell; Donald C Sheppard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-20       Impact factor: 11.205

2.  Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.

Authors:  Ateesha Farah Mohamed; F Reed Johnson; Maria-Magdalena Balp; Frederico Calado
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

3.  Spatial Mapping of Pyocyanin in Pseudomonas Aeruginosa Bacterial Communities Using Surface Enhanced Raman Scattering.

Authors:  Sneha Polisetti; Nameera F Baig; Nydia Morales-Soto; Joshua D Shrout; Paul W Bohn
Journal:  Appl Spectrosc       Date:  2016-07-20       Impact factor: 2.388

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

6.  Which bacterial biofilm exopolysaccharide is preferred, Psl or alginate?

Authors:  Michael J Schurr
Journal:  J Bacteriol       Date:  2013-02-15       Impact factor: 3.490

7.  An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.

Authors:  Martina Koeva; Alina D Gutu; Wesley Hebert; Jeffrey D Wager; Lael M Yonker; George A O'Toole; Frederick M Ausubel; Samuel M Moskowitz; Diane Joseph-McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

8.  The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.

Authors:  Sladjana Skopelja; B JoNell Hamilton; Jonathan D Jones; Mei-Ling Yang; Mark Mamula; Alix Ashare; Alex H Gifford; William Fc Rigby
Journal:  JCI Insight       Date:  2016-10-20

9.  Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

Authors:  Jocelyn Y Ang; Nahed Abdel-Haq; Frank Zhu; Abrar K Thabit; David P Nicolau; Michael J Satlin; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  Pseudomonas aeruginosa Alginate Benefits Staphylococcus aureus?

Authors:  Michael J Schurr
Journal:  J Bacteriol       Date:  2020-03-26       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.